KLK3 and prostate carcinoma: Based on this scoping and refinement exercise, the Task Force decided to update their 2014 guideline on prostate cancer screening since additional primary study evidence (e.g., the Cluster Randomized Trial of PSA Testing for Prostate Cancer) and additional follow-up from previously included studies (e.g., prostate, lung, colorectal, and ovarian cancer screening trial and ERSPC) have been published [69, 70, 86].